$5.67 0.36 (+6.78%)
7/2/2009 4:00 PM

Orexigen Therapeutics, Inc. (OREX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity.

Current Price $5.67 Mkt Cap $184.26M
Open $0.00 P/E Ratio 5.91
Prev. Close $5.31 Div. (Yield) N/A (N/A)
Daily Range $5.00 - $5.69 Volume 0
52-Wk Range $1.55 - $12.28 Avg. Daily Vol. 0

OREX News and Articles

All stories about OREX

Caps

How do you think OREX will perform vs the S&P 500?

Add Stock to Watchlist

All Members

54 Outperform
28 Underperform
 

All-Star Members

23 Outperform
14 Underperform
 

Wall Street

7 Outperform
0 Underperform
 

Top OREX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

fiordwalker (21.90)
Submitted March 25, 2008

weight loss drug could be a blockbuster

albanyfx (52.42)
Submitted February 29, 2008

OREX management panicked and accepted any horrible deal to get their hands on some cash. But there are a whole host of medical, technology, finance, manufacturing and retail names out there that are starving for capital. And you better believe that… More

OREX VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about OREX.

Recs

0
Member Avatar LimoDriver1971 (97.18) Submitted: 7/1/2009 9:53:34 AM : Outperform Start Price: $5.27 OREX Score: +10.59

My swecond pick related to the trend in this nation focusing on obesity.

As these new television shows start to portray overweight people in a more positive (help-able) light, this segment of doctors will come to the limelight, and will need the drugs and hardware to perform the operations and the maintenance that these people need.

Recs

0
Member Avatar quinpeung (49.53) Submitted: 6/3/2009 3:21:12 PM : Underperform Start Price: $4.38 OREX Score: -35.01

Surprised that OREX rose back over the threshold. This stock will likely bounce up and down for the next few months as management hypes their marginal obesity candidate.

Recs

0
Member Avatar zzlangerhans (99.57) Submitted: 6/2/2009 11:53:01 PM : Underperform Start Price: $4.19 OREX Score: -40.82

I'm suspicious of strong upward moves in Orexigen given the weakness of the completed phase III trial of Contrave. The company has an opportunity to redeem itself in Q3 with additional phase III Contrave data as well as phase II data for Empatic, but I don't see current highs being sustained through that point.

Leaderboard

Find the members with the highest scoring picks in OREX.

Score Leader

bigsmitty52

bigsmitty52 (98.68) Score: +94.49

You can't go wrong betting on Americans getting fatter.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
bigsmitty52 98.68 3/20/2009 Outperform 1Y $2.69 +110.78% +16.29% +94.49 1 Comment
pdt24 < 20 3/30/2009 Outperform 5Y $2.80 +102.50% +13.24% +89.26
manetheren86 96.99 5/18/2009 Outperform 5Y $3.03 +87.13% -0.65% +87.78
gerbs87 86.21 5/12/2009 Outperform NS $3.09 +83.50% -1.99% +85.48
Renton405 61.79 5/12/2009 Outperform 5Y $3.09 +83.50% -1.99% +85.48
cschier 62.10 5/15/2009 Outperform 5Y $3.09 +83.50% +0.49% +83.00
portefeuille 99.98 5/27/2009 Outperform 3Y $3.14 +80.57% -1.78% +82.36
Gemini846 91.80 5/27/2009 Outperform NS $3.14 +80.57% -1.78% +82.36
CRAZYCAPTAIN 99.30 5/4/2009 Outperform 1Y $3.10 +82.90% +1.42% +81.48
ProCreditXpress 77.56 5/26/2009 Outperform NS $3.10 +82.90% +1.64% +81.26

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackRodmanRen 81.15 6/24/2009 Outperform NS $4.73 +19.88% -1.19% +21.06
TrackLeerinkSwan 93.59 8/25/2008 Outperform NS $11.51 -50.74% -30.27% -20.47
TrackCowenandCo 78.61 4/3/2008 Outperform NS $10.56 -46.31% -33.96% -12.34
TrackLazardCapit 41.24 2/6/2008 Outperform NS $11.67 -51.41% -33.22% -18.20
TrackCanaccord 87.33 2/4/2008 Outperform NS $11.59 -51.08% -35.24% -15.84
TrackJPMorgan 82.92 6/7/2007 Outperform NS $17.76 -68.07% -40.74% -27.33
TrackJMP 29.30 6/6/2007 Outperform NS $18.35 -69.10% -41.27% -27.83

Featured Broker Partners